APAC Acute Myeloid Leukemia Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Asia-Pacific acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.1% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Asia-Pacific Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 And Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific acute myeloid leukemia diagnostics market are:

Initiatives by the government and other authorities for life sciences and funding

Increasing diagnostic products for leukemia cancer

Market Players

The key market players in the Asia-Pacific acute myeloid leukemia diagnostics market are listed below:

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

QIAGEN

Abbott

Siemens Healthcare GmbH

Merck KGAA

Hologic, Inc.

Agilent Technologies, Inc.

DiaSorin S.p.A.

Illumina, Inc.

BIOMERIEUX

Myriad Genetics, Inc.

Quest Diagnostics Incorporated.

Bio-Rad Laboratories, Inc.

Koninklijke Philips N.V.

Exact Sciences Corporation

Time Medical Holding

PlexBio

MinFound Medical Systems Co., Ltd

Medonica Co. LTD

CANON MEDICAL SYSTEMS CORPORATION

FONAR CORP.

Sysmex Corporation

1 INTRODUCTION 53

1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT TYPE LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET END USER COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71

3 EXECUTIVE SUMMARY 72

4 PREMIUM INSIGHTS 75

4.1 PESTEL ANALYSIS 76
4.2 PORTER'S 5 FORCES 77

5 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 78

5.1 REGULATORY SCENARIO IN THE U.S. 78
5.2 REGULATORY SCENARIO IN AUSTRALIA 79
5.3 REGULATORY SCENARIO IN JAPAN 79
5.4 REGULATORY SCENARIO IN CHINA 79

6 MARKET OVERVIEW 81

6.1 DRIVERS 83
- 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 83
- 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 85
- 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 85
- 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 86
6.2 RESTRAINTS 87
- 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 87
- 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 87
6.3 OPPORTUNITIES 88
- 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 88
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 88
- 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 89
6.4 CHALLENGES 90
- 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 90
- 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 90

7 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 91

7.1 OVERVIEW 92
7.2 INSTRUMENTS 95
- 7.2.1 BIOPSY INSTRUMENTS 96
  - 7.2.1.1 BONE MARROW BIOPSY 96
  - 7.2.1.2 NEEDLE BIOPSY 96
  - 7.2.1.3 SURGICAL BIOPSY 96
  - 7.2.1.4 OTHERS 97
- 7.2.2 PATHOLOGY-BASED INSTRUMENTS 97
  - 7.2.2.1 PCR INSTRUMENTS 97
  - 7.2.2.2 SLIDE STAINING SYSTEMS 97
  - 7.2.2.3 TISSUE PROCESSING SYSTEMS 97
  - 7.2.2.4 CELL PROCESSORS 97
  - 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 98
- 7.2.3 IMAGING INSTRUMENTS 98
  - 7.2.3.1 ULTRASOUND SYSTEMS 98
  - 7.2.3.2 CT SYSTEMS 98
  - 7.2.3.3 MRI SYSTEMS 98
  - 7.2.3.4 OTHERS 98
- 7.2.4 OTHERS 98
7.3 CONSUMABLES & ACCESSORIES 99
- 7.3.1 KITS 100
  - 7.3.1.1 PCR KITS 100
  - 7.3.1.2 DNA POLYMERASE KITS 100
  - 7.3.1.3 NUCLEIC ACID ISOLATION KITS 100
  - 7.3.1.4 OTHERS 101
- 7.3.2 REAGENTS 101
  - 7.3.2.1 ASSAYS 101
  - 7.3.2.2 BUFFERS 101
  - 7.3.2.3 PRIMERS 101
  - 7.3.2.4 OTHERS 101
- 7.3.3 PROBES 102
- 7.3.4 OTHER CONSUMABLES 102

8 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 103

8.1 OVERVIEW 104
8.2 BLOOD TEST 107
- 8.2.1 COMPLETE BLOOD COUNT (CBC) 108
- 8.2.2 BLOOD CHEMISTRY TESTS 108
- 8.2.3 OTHERS 108
8.3 IMAGING TEST 108
- 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 109
- 8.3.2 MRI 109
- 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 110
- 8.3.4 OTHERS 110
8.4 BONE MARROW TESTS 110
- 8.4.1 BONE MARROW ASPIRATE 111
- 8.4.2 BONE MARROW BIOPSY 111
- 8.4.3 OTHERS 111
8.5 GENETIC TESTS 111
- 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 112
- 8.5.2 KARYOTYPING 112
- 8.5.3 OTHERS 112
8.6 BIOMARKER TEST 112
- 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
- 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 113
- 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 114
8.7 IMMUNOPHENOTYPING 114
- 8.7.1 FLOW CYTOMETRY 115
- 8.7.2 IMMUNOHISTOCHEMISTRY 115
- 8.7.3 OTHERS 115
8.8 OTHERS 115

9 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 117

9.1 OVERVIEW 118
9.2 MYELOBLASTIC (M0) 121
9.3 MYELOBLASTIC (M1) 121
9.4 MYELOBLASTIC (M2) 122
9.5 PROMYELOCYTIC (M3) 123
9.6 MYELOMONOCYTIC (M4) 124
9.7 MONOCYTIC (M5) 124
9.8 ERYTHROLEUKEMIA (M6) 125
9.9 MEGAKARYOCYTIC (M7) 126

10 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127

10.1 OVERVIEW 128
10.2 65 AND ABOVE 131
10.3 30-65 131
10.4 BELOW 21 132
10.5 21-29 133

11 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 135

11.1 OVERVIEW 136
11.2 MALE 139
11.3 FEMALE 139

12 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 141

12.1 OVERVIEW 142
12.2 HOSPITALS 145
12.3 ASSOCIATED LABS 145
12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 146
12.5 DIAGNOSTIC IMAGING CENTERS 147
12.6 CANCER RESEARCH INSTITUTES 147
12.7 OTHERS 148

13 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 150

13.1 OVERVIEW 151
13.2 DIRECT TENDER 154
13.3 RETAIL SALES 154

14 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 156

14.1 ASIA-PACIFIC 157
- 14.1.1 CHINA 169
- 14.1.2 JAPAN 175
- 14.1.3 INDIA 181
- 14.1.4 AUSTRALIA 187
- 14.1.5 SOUTH KOREA 193
- 14.1.6 INDONESIA 199
- 14.1.7 PHILIPPINES 205
- 14.1.8 THAILAND 211
- 14.1.9 MALAYSIA 217
- 14.1.10 VIETNAM 223
- 14.1.11 SINGAPORE 229
- 14.1.12 REST OF ASIA-PACIFIC 235

15 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 236

15.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 236

16 SWOT ANALYSIS 237

17 COMPANY PROFILE 238

17.1 CANON MEDICAL SYSTEMS CORPORATION. 238
- 17.1.1 COMPANY SNAPSHOT 238
- 17.1.2 REVENUE ANALYSIS 238
- 17.1.3 COMPANY SHARE ANALYSIS 239
- 17.1.4 PRODUCT PORTFOLIO 239
- 17.1.5 RECENT DEVELOPMENT 239
17.2 SYSMEX CORPORATION 240
- 17.2.1 COMPANY SNAPSHOT 240
- 17.2.2 REVENUE ANALYSIS 240
- 17.2.3 COMPANY SHARE ANALYSIS 241
- 17.2.4 PRODUCT PORTFOLIO 241
- 17.2.5 RECENT DEVELOPMENT 241
17.3 EPIGENOMICS AG. 242
- 17.3.1 COMPANY SNAPSHOT 242
- 17.3.2 REVENUE ANALYSIS 242
- 17.3.3 COMPANY SHARE ANALYSIS 243
- 17.3.4 PRODUCT PORTFOLIO 243
- 17.3.5 RECENT DEVELOPMENT 243
17.4 MYRIAD GENETICS, INC
- 17.4.1 COMPANY SNAPSHOT 244
- 17.4.2 REVENUE ANALYSIS 244
- 17.4.3 COMPANY SHARE ANALYSIS 245
- 17.4.4 PRODUCT PORTFOLIO 245
- 17.4.5 RECENT DEVELOPMENT 245
17.5 F. HOFFMANN- LA ROCHE LTD 246
- 17.5.1 COMPANY SNAPSHOT 246
- 17.5.2 REVENUE ANALYSIS 246
- 17.5.3 COMPANY SHARE ANALYSIS 247
- 17.5.4 PRODUCT PORTFOLIO 247
- 17.5.5 RECENT DEVELOPMENT 247
17.6 ABBOTT 248
- 17.6.1 COMPANY SNAPSHOT 248
- 17.6.2 REVENUE ANALYSIS 248
- 17.6.3 PRODUCT PORTFOLIO 249
- 17.6.4 RECENT DEVELOPMENT 249
17.7 AGILENT TECHNOLOGIES, INC. 250
- 17.7.1 COMPANY SNAPSHOT 250
- 17.7.2 REVENUE ANALYSIS 250
- 17.7.3 PRODUCT PORTFOLIO 251
- 17.7.4 RECENT DEVELOPMENT 251
17.8 BD 252
- 17.8.1 COMPANY SNAPSHOT 252
- 17.8.2 REVENUE ANALYSIS 252
- 17.8.3 PRODUCT PORTFOLIO 253
- 17.8.4 RECENT DEVELOPMENT 253
17.9 BIOMERIEUX 254
- 17.9.1 COMPANY SNAPSHOT 254
- 17.9.2 PRODUCT PORTFOLIO 254
- 17.9.3 RECENT DEVELOPMENT 254
17.10 BIO-RAD LABORATORIES, INC. 255
- 17.10.1 COMPANY SNAPSHOT 255
- 17.10.2 REVENUE ANALYSIS 255
- 17.10.3 PRODUCT PORTFOLIO 256
- 17.10.4 RECENT DEVELOPMENT 256
17.11 DIASORIN S.P.A. 257
- 17.11.1 COMPANY SNAPSHOT 257
- 17.11.2 REVENUE ANALYSIS 257
- 17.11.3 PRODUCT PORTFOLIO 258
- 17.11.4 RECENT DEVELOPMENTS 258
17.12 EXACT SCIENCES CORPORATION 259
- 17.12.1 COMPANY SNAPSHOT 259
- 17.12.2 REVENUE ANALYSIS 259
- 17.12.3 PRODUCT PORTFOLIO 260
- 17.12.4 RECENT DEVELOPMENTS 260
17.13 FONAR CORP. 261
- 17.13.1 COMPANY SNAPSHOT 261
- 17.13.2 REVENUE ANALYSIS 261
- 17.13.3 PRODUCT PORTFOLIO 262
- 17.13.4 RECENT DEVELOPMENT 262
17.14 HOLOGIC INC. 263
- 17.14.1 COMPANY SNAPSHOT 263
- 17.14.2 REVENUE ANALYSIS 263
- 17.14.3 PRODUCT PORTFOLIO 264
- 17.14.4 RECENT DEVELOPMENT 264
17.15 ILLUMINA, INC. 265
- 17.15.1 COMPANY SNAPSHOT 265
- 17.15.2 REVENUE ANALYSIS 265
- 17.15.3 PRODUCT PORTFOLIO 266
- 17.15.4 RECENT DEVELOPMENT 266
17.16 KONINKLIJKE PHILIPS N.V. 267
- 17.16.1 COMPANY SNAPSHOT 267
- 17.16.2 REVENUE ANALYSIS 267
- 17.16.3 PRODUCT PORTFOLIO 268
- 17.16.4 RECENT DEVELOPMENT 268
17.17 MEDONICA CO. LTD 269
- 17.17.1 COMPANY SNAPSHOT 269
- 17.17.2 PRODUCT PORTFOLIO 269
- 17.17.3 RECENT DEVELOPMENT 269
17.18 MERCK KGAA 270
- 17.18.1 COMPANY SNAPSHOT 270
- 17.18.2 REVENUE ANALYSIS 270
- 17.18.3 PRODUCT PORTFOLIO 271
- 17.18.4 RECENT DEVELOPMENTS 271
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 272
- 17.19.1 COMPANY SNAPSHOT 272
- 17.19.2 PRODUCT PORTFOLIO 272
- 17.19.3 RECENT DEVELOPMENT 272

17.20 PLEXBIO 273
- 17.20.1 COMPANY SNAPSHOT 273
- 17.20.2 PRODUCT PORTFOLIO 273
- 17.20.3 RECENT DEVELOPMENTS 273
17.21 QIAGEN 274
- 17.21.1 COMPANY SNAPSHOT 274
- 17.21.2 REVENUE ANALYSIS 274
- 17.21.3 PRODUCT PORTFOLIO 275
- 17.21.4 RECENT DEVELOPMENTS 275
17.22 QUEST DIAGNOSTICS INCORPORATED 276
- 17.22.1 COMPANY SNAPSHOT 276
- 17.22.2 REVENUE ANALYSIS 276
- 17.22.3 PRODUCT PORTFOLIO 277
- 17.22.4 RECENT DEVELOPMENTS 277
17.23 SIEMENS HEALTHCARE GMBH 278
- 17.23.1 COMPANY SNAPSHOT 278
- 17.23.2 REVENUE ANALYSIS 278
- 17.23.3 PRODUCT PORTFOLIO 279
- 17.23.4 RECENT DEVELOPMENT 279
17.24 SONIC HEALTHCARE 280
- 17.24.1 COMPANY SNAPSHOT 280
- 17.24.2 PRODUCT PORTFOLIO 280
- 17.24.3 RECENT DEVELOPMENT 280
17.25 STERNMED GMBH 281
- 17.25.1 COMPANY SNAPSHOT 281
- 17.25.2 PRODUCT PORTFOLIO 281
- 17.25.3 RECENT DEVELOPMENTS 281
17.26 THERMO FISHER SCIENTIFIC INC. 282
- 17.26.1 COMPANY SNAPSHOT 282
- 17.26.2 REVENUE ANALYSIS 282
- 17.26.3 PRODUCT PORTFOLIO 283
- 17.26.4 RECENT DEVELOPMENT 283
17.27 TIME MEDICAL HOLDING 284
- 17.27.1 COMPANY SNAPSHOT 284
- 17.27.2 PRODUCT PORTFOLIO 284
- 17.27.3 RECENT DEVELOPMENT 284

18 QUESTIONNAIRE 285

19 RELATED REPORTS 289

LIST OF TABLES

TABLE 1 APPROVED DIAGNOSTICS OF LEUKEMIA 65
TABLE 2 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 71
TABLE 3 ASIA PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 4 ASIA PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 5 ASIA PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 73
TABLE 6 ASIA PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 74
TABLE 7 ASIA PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 75
TABLE 8 ASIA PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 9 ASIA PACIFIC CONSUMABLES AND ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77
TABLE 10 ASIA PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 77
TABLE 11 ASIA PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 78
TABLE 12 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 83
TABLE 13 ASIA PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 14 ASIA PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 85
TABLE 15 ASIA PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 16 ASIA PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 86
TABLE 17 ASIA PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 18 ASIA PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 88
TABLE 19 ASIA PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 20 ASIA PACIFIC GENETIC TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 89
TABLE 21 ASIA PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 22 ASIA PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 90
TABLE 23 ASIA PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 24 ASIA PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 91
TABLE 25 ASIA PACIFIC OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 26 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 97
TABLE 27 ASIA PACIFIC MYELOBLASTIC (M0) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 28 ASIA PACIFIC MYELOBLASTIC (M1) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 99
TABLE 29 ASIA PACIFIC MYELOBLASTIC (M2) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 30 ASIA PACIFIC PROMYELOCYTIC (M3) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
TABLE 31 ASIA PACIFIC MYELOMONOCYTIC (M4) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 101
TABLE 32 ASIA PACIFIC MONOCYTIC (M5) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 33 ASIA PACIFIC ERYTHROLEUKEMIA (M6) IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
TABLE 34 ASIA PACIFIC MEGAKARYOCYTIC (M7) ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 103
TABLE 35 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 107
TABLE 36 ASIA PACIFIC 65 AND ABOVE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 37 ASIA PACIFIC 30-65 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 38 ASIA PACIFIC BELOW 21 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 110
TABLE 39 ASIA PACIFIC 21-29 IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 111
TABLE 40 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 115
TABLE 41 ASIA PACIFIC MALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
TABLE 42 ASIA PACIFIC FEMALE IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
TABLE 43 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 121
TABLE 44 ASIA PACIFIC HOSPITALS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 122
TABLE 45 ASIA PACIFIC ASSOCIATED LABS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 46 ASIA PACIFIC INDEPENDENT DIAGNOSTIC LABORATORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
TABLE 47 ASIA PACIFIC DIAGNOSTIC IMAGING CENTERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
TABLE 48 ASIA PACIFIC CANCER RESEARCH INSTITUTES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
TABLE 49 ASIA PACIFIC OTHERS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
TABLE 50 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 130
TABLE 51 ASIA PACIFIC DIRECT TENDER IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 131
TABLE 52 ASIA PACIFIC RETAIL SALES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 132
TABLE 53 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 139
TABLE 54 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 55 ASIA-PACIFIC INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 139
TABLE 56 ASIA-PACIFIC PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 57 ASIA-PACIFIC IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 58 ASIA-PACIFIC BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 140
TABLE 59 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 60 ASIA-PACIFIC KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 61 ASIA-PACIFIC REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 141
TABLE 62 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 63 ASIA-PACIFIC IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 64 ASIA-PACIFIC BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 142
TABLE 65 ASIA-PACIFIC BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 66 ASIA-PACIFIC BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 67 ASIA-PACIFIC IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 68 ASIA-PACIFIC GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
TABLE 69 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 144
TABLE 70 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 144
TABLE 71 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 144
TABLE 72 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 145
TABLE 73 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 145
TABLE 74 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 75 CHINA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 76 CHINA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 146
TABLE 77 CHINA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 78 CHINA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 79 CHINA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 80 CHINA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 147
TABLE 81 CHINA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 148
TABLE 82 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 83 CHINA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 148
TABLE 84 CHINA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 85 CHINA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 86 CHINA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 87 CHINA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
TABLE 88 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 150
TABLE 89 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 150
TABLE 90 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 150
TABLE 91 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 151
TABLE 92 CHINA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 151
TABLE 93 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 94 JAPAN INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 95 JAPAN PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 152
TABLE 96 JAPAN IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
TABLE 97 JAPAN BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
TABLE 98 JAPAN CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
TABLE 99 JAPAN KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 153
TABLE 100 JAPAN REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 154
TABLE 101 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 102 JAPAN IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 154
TABLE 103 JAPAN BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 104 JAPAN BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 105 JAPAN BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 106 JAPAN IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
TABLE 107 JAPAN GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
TABLE 108 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 156
TABLE 109 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 156
TABLE 110 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 157
TABLE 111 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 157
TABLE 112 JAPAN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 157
TABLE 113 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 114 INDIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 115 INDIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 158
TABLE 116 INDIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
TABLE 117 INDIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
TABLE 118 INDIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 159
TABLE 119 INDIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 160
TABLE 120 INDIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 160
TABLE 121 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 160
TABLE 122 INDIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 123 INDIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 124 INDIA BLOOD TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 125 INDIA BIOMARKER TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
TABLE 126 INDIA IMMUNOPHENOTYPING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 127 INDIA GENETIC TESTING IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
TABLE 128 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 162
TABLE 129 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 163
TABLE 130 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION) 163
TABLE 131 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 163
TABLE 132 INDIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 163
TABLE 133 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 134 AUSTRALIA INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 135 AUSTRALIA PATHOLOGY-BASED INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 164
TABLE 136 AUSTRALIA IMAGING INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
TABLE 137 AUSTRALIA BIOPSY INSTRUMENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
TABLE 138 AUSTRALIA CONSUMABLES & ACCESSORIES IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
TABLE 139 AUSTRALIA KITS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 165
TABLE 140 AUSTRALIA REAGENTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 166
TABLE 141 AUSTRALIA ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
TABLE 142 AUSTRALIA IMAGING TEST IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 166
TABLE 143 AUSTRALIA BONE MARROW TESTS IN ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167

LIST OF FIGURES

FIGURE 1 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION 35
FIGURE 2 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DATA TRIANGULATION 38
FIGURE 3 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DROC ANALYSIS 39
FIGURE 4 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 40
FIGURE 5 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : COMPANY RESEARCH ANALYSIS 40
FIGURE 6 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : INTERVIEW DEMOGRAPHICS 42
FIGURE 7 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : DBMR MARKET POSITION GRID 43
FIGURE 8 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : MARKET END USER COVERAGE GRID 45
FIGURE 9 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : VENDOR SHARE ANALYSIS 46
FIGURE 10 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET : SEGMENTATION 50
FIGURE 11 THE GROWING PREVALENCE OF LEUKEMIA CANCER IS EXPECTED TO DRIVE THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN THE FORECAST PERIOD 51
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET IN 2023 & 2030 51
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 58
FIGURE 14 NUMBER OF PREVALENCE OF LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 60
FIGURE 15 FIVE YEARS PREVALENCE LEUKEMIA INCIDENCE WORLDWIDE (BOTH SEXES) 60
FIGURE 16 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022 68
FIGURE 17 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION) 69
FIGURE 18 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030) 69
FIGURE 19 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 70
FIGURE 20 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2022 80
FIGURE 21 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION) 81
FIGURE 22 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030) 81
FIGURE 23 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE 82
FIGURE 24 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2022 94
FIGURE 25 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION) 95
FIGURE 26 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030) 95
FIGURE 27 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE 96
FIGURE 28 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2022 104
FIGURE 29 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 105
FIGURE 30 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 105
FIGURE 31 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 106
FIGURE 32 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2022 112
FIGURE 33 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION) 113
FIGURE 34 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030) 113
FIGURE 35 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE 114
FIGURE 36 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2022 118
FIGURE 37 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION) 119
FIGURE 38 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030) 119
FIGURE 39 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE 120
FIGURE 40 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022 127
FIGURE 41 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 128
FIGURE 42 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 128
FIGURE 43 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 129
FIGURE 44 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: SNAPSHOT (2022) 134
FIGURE 45 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022) 136
FIGURE 46 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 136
FIGURE 47 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 137
FIGURE 48 ASIA-PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030) 137
FIGURE 49 ASIA PACIFIC ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 212